open access

Vol 87, No 5 (2019)
REVIEWS
Published online: 2019-10-31
Submitted: 2019-05-27
Accepted: 2019-07-03
Get Citation

Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm

Mutlay Sayan, Mehmet Fuat Eren, Apar Gupta, Nisha Ohri, Ayse Kotek, Ibrahim Babalioglu, Sedenay Oskeroglu Kaplan, Ozge Duran, Ozlem Derinalp Or, Funda Cukurcayir, Neslihan Kurtul, Beyhan Ceylaner Bicakci, Tugce Kutuk, Sukran Senyurek, Ali Turk, Salma K Jabbour, Banu Atalar
DOI: 10.5603/ARM.2019.0051
·
Pubmed: 31680229
·
Adv Respir Med 2019;87(5):289-297.

open access

Vol 87, No 5 (2019)
REVIEWS
Published online: 2019-10-31
Submitted: 2019-05-27
Accepted: 2019-07-03

Abstract

Malignant pleural mesothelioma (MPM) is a rare disease with a poor prognosis. The main therapeutic options for MPM include surgery, chemotherapy, and radiation therapy (RT). Although multimodality therapy has been reported to improve survival, not every medically operable patient is able to undergo all recommended therapy. With improvements in surgical techniques and systemic therapies, as well as advancements in RT, there has been a potential new paradigm in the management of this disease. In this review, we discuss the current literature on MPM management and propose a functional treatment algorithm.

Abstract

Malignant pleural mesothelioma (MPM) is a rare disease with a poor prognosis. The main therapeutic options for MPM include surgery, chemotherapy, and radiation therapy (RT). Although multimodality therapy has been reported to improve survival, not every medically operable patient is able to undergo all recommended therapy. With improvements in surgical techniques and systemic therapies, as well as advancements in RT, there has been a potential new paradigm in the management of this disease. In this review, we discuss the current literature on MPM management and propose a functional treatment algorithm.

Get Citation

Keywords

mesothelioma, surgery, chemotherapy, radiotherapy

About this article
Title

Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm

Journal

Advances in Respiratory Medicine

Issue

Vol 87, No 5 (2019)

Pages

289-297

Published online

2019-10-31

DOI

10.5603/ARM.2019.0051

Pubmed

31680229

Bibliographic record

Adv Respir Med 2019;87(5):289-297.

Keywords

mesothelioma
surgery
chemotherapy
radiotherapy

Authors

Mutlay Sayan
Mehmet Fuat Eren
Apar Gupta
Nisha Ohri
Ayse Kotek
Ibrahim Babalioglu
Sedenay Oskeroglu Kaplan
Ozge Duran
Ozlem Derinalp Or
Funda Cukurcayir
Neslihan Kurtul
Beyhan Ceylaner Bicakci
Tugce Kutuk
Sukran Senyurek
Ali Turk
Salma K Jabbour
Banu Atalar

References (98)
  1. Jaurand MC, Fleury-Feith J. Pathogenesis of malignant pleural mesothelioma. Respirology. 2005; 10(1): 2–8.
  2. Mossman BT, Kamp DW, Weitzman SA. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest. 1996; 14(5): 466–480.
  3. Baris I, Simonato L, Artvinli M, et al. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int J Cancer. 1987; 39(1): 10–17.
  4. Emri S, Demir AU. Malignant pleural mesothelioma in Turkey, 2000–2002. Lung Cancer. 2004; 45 Suppl 1: S17–S20.
  5. Giordani M, Mattioli M, Ballirano P, et al. Geological occurrence, mineralogical characterization, and risk assessment of potentially carcinogenic erionite in Italy. J Toxicol Environ Health B Crit Rev. 2017; 20(2): 81–103.
  6. Van Gosen BS, Blitz TA, Plumlee GS, et al. Geologic occurrences of erionite in the United States: an emerging national public health concern for respiratory disease. Environ Geochem Health. 2013; 35(4): 419–430.
  7. Timblin CR, Guthrie GD, Janssen YW, et al. Patterns of c-fos and c-jun proto-oncogene expression, apoptosis, and proliferation in rat pleural mesothelial cells exposed to erionite or asbestos fibers. Toxicol Appl Pharmacol. 1998; 151(1): 88–97.
  8. Janssen YM, Heintz NH, Marsh JP, et al. Induction of c-fos and c-jun proto-oncogenes in target cells of the lung and pleura by carcinogenic fibers. Am J Respir Cell Mol Biol. 1994; 11(5): 522–530.
  9. Fach E, Waldman WJ, Williams M, et al. Analysis of the biological and chemical reactivity of zeolite-based aluminosilicate fibers and particulates. Environ Health Perspect. 2002; 110(11): 1087–1096.
  10. Carthew P, Hill RJ, Edwards RE, et al. Intrapleural administration of fibres induces mesothelioma in rats in the same relative order of hazard as occurs in man after exposure. Hum Exp Toxicol. 1992; 11(6): 530–534.
  11. Wagner JC, Skidmore JW, Hill RJ, et al. Erionite exposure and mesotheliomas in rats. Br J Cancer. 1985; 51(5): 727–730.
  12. Carbone M, Yang H. Mesothelioma: recent highlights. Ann Transl Med. 2017; 5(11): 238.
  13. Baas P, Fennell D, Kerr KM, et al. ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5: v31–v39.
  14. Olsen NJ, Franklin PJ, Reid A, et al. Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust. 2011; 195(5): 271–274.
  15. Frank AL, Joshi TK. The global spread of asbestos. Ann Glob Health. 2014; 80(4): 257–262.
  16. Hashim D, Boffetta P. Occupational and environmental exposures and cancers in developing countries. Ann Glob Health. 2014; 80(5): 393–411.
  17. Opitz I, Friess M, Kestenholz P, et al. A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma: a review of 12 years' experience. J Thorac Oncol. 2015; 10(11): 1634–1641.
  18. Abdel-Rahman O, Elsayed Z, Mohamed H, et al. Radical multimodality therapy for malignant pleural mesothelioma. Cochrane Database Syst Rev. 2018; 1: CD012605.
  19. Batirel HF. Extrapleural pneumonectomy (EPP) pleurectomy decortication (P/D). Ann Transl Med. 2017; 5(11): 232.
  20. Rice D, Rusch V, Pass H, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol. 2011; 6(8): 1304–1312.
  21. Rusch VW, Chansky K, Kindler HL, et al. The IASLC mesothelioma staging project: proposals for the m descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J Thorac Oncol. 2016; 11(12): 2112–2119.
  22. Opitz I, Weder W. A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma. Ann Transl Med. 2017; 5(11): 237.
  23. Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012; 7(11): 1631–1639.
  24. Hasani A, Alvarez JM, Wyatt JMa, et al. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol. 2009; 4(8): 1010–1016.
  25. Sugarbaker D, Flores R, Jaklitsch M, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg. 1999; 117(1): 54–65.
  26. Bovolato P, Casadio C, Billè A, et al. Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014; 9(3): 390–396.
  27. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg. 2002; 22(2): 298–305.
  28. Branscheid D, Krysa S, Bauer E, et al. Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 1991; 5(9): 466–72; discussion 473.
  29. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008; 135(3): 620–6, 626.e1.
  30. Kostron A, Friess M, Inci I, et al. Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients. Interact Cardiovasc Thorac Surg. 2017; 24(5): 740–746.
  31. Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol. 2012; 7(4): 737–743.
  32. Luckraz H, Rahman M, Patel N, et al. Three decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur J Cardiothorac Surg. 2010; 37(3): 552–556.
  33. Miyazaki T, Yamasaki N, Tsuchiya T, et al. Is pleurectomy/decortication superior to extrapleural pneumonectomy for patients with malignant pleural mesothelioma? A single-institutional experience. Ann Thorac Cardiovasc Surg. 2018; 24(2): 81–88.
  34. Okada M, Mimura T, Ohbayashi C, et al. Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg. 2008; 7(1): 102–106.
  35. Pass HI, Kranda K, Temeck BK, et al. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol. 1997; 4(3): 215–222.
  36. Rena O, Casadio C. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure. Lung Cancer. 2012; 77(1): 151–155.
  37. Sharkey AJ, Tenconi S, Nakas A, et al. The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication. Eur J Cardiothorac Surg. 2016; 49(6): 1632–1641.
  38. Kai Y, Tsutani Y, Tsubokawa N, et al. Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma. Oncol Lett. 2019; 17(3): 3607–3614.
  39. Cao C, Akhunji Z, Fu B, et al. Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma. Lung Cancer. 2013; 81(3): 319–327.
  40. Taioli E, Wolf AS, Flores RM. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg. 2015; 99(2): 472–480.
  41. Treasure T, Lang-Lazdunski L, Waller D, et al. MARS trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011; 12(8): 763–772.
  42. Domen A, De Laet C, Vanderbruggen W, et al. Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period. Acta Chir Belg. 2017; 117(3): 157–163.
  43. Rosenzweig KE, Zauderer MG, Laser B, et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2012; 83(4): 1278–1283.
  44. Bille A, Belcher E, Raubenheimer H, et al. Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals. Gen Thorac Cardiovasc Surg. 2012; 60(5): 289–296.
  45. Stahel RA, Riesterer O, Xyrafas A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015; 16(16): 1651–1658.
  46. Hasegawa S, Okada M, Tanaka F, et al. Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial). Int J Clin Oncol. 2016; 21(3): 523–530.
  47. Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010; 36(6): 1362–1369.
  48. Federico R, Adolfo F, Giuseppe M, et al. Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma. BMC Cancer. 2013; 13: 22.
  49. de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009; 27(9): 1413–1418.
  50. Rimner A, Zauderer MG, Gomez DR, et al. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. J Clin Oncol. 2016; 34(23): 2761–2768.
  51. Minatel E, Trovo M, Bearz A, et al. Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure, and prognostic factors. Int J Radiat Oncol Biol Phys. 2015; 93(3): 606–613.
  52. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009; 27(18): 3007–3013.
  53. Bölükbas S, Manegold C, Eberlein M, et al. Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy. Lung Cancer. 2011; 71(1): 75–81.
  54. Buduhan G, Menon S, Aye R, et al. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2009; 88(3): 870–5; discussion 876.
  55. Fahrner R, Ochsenbein A, Schmid RA, et al. Long term survival after trimodal therapy in malignant pleural mesothelioma. Swiss Med Wkly. 2012; 142: w13686.
  56. Kimura T, Doi Y, Nakashima T, et al. Clinical experience of volumetric modulated arc therapy for malignant pleural mesothelioma after extrapleural pneumonectomy. J Radiat Res. 2015; 56(2): 315–324.
  57. Thieke C, Nicolay NH, Sterzing F, et al. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol. 2015; 10: 267.
  58. Trousse DS, Avaro JP, D'Journo XB, et al. Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg. 2009; 36(4): 759–763.
  59. Lang-Lazdunski L, Bille A, Papa S, et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2011; 6(10): 1746–1752.
  60. Blomberg C, Nilsson J, Holgersson G, et al. Randomized trials of systemic medically-treated malignant mesothelioma: a systematic review. Anticancer Res. 2015; 35(5): 2493–2501.
  61. Kelly RJ, Sharon E, Hassan R. Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer. 2011; 73(3): 256–263.
  62. Ellis P, Davies AM, Evans WK, et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol. 2006; 1(6): 591–601.
  63. Zauderer MG, Kass SL, Woo K, et al. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer. 2014; 84(3): 271–274.
  64. Jänne P, Wozniak A, Belani C, et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006; 1(6): 506–512.
  65. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008; 26(10): 1698–1704.
  66. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009; 63(1): 94–97.
  67. Verma V, Wegner RE, Brooks ED, et al. Chemotherapy versus supportive care for unresected malignant pleural mesothelioma. Clin Lung Cancer. 2019; 20(4): 263–269.
  68. Metintas M, Ak G, Erginel S, et al. A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 A single institution experience. Lung Cancer. 2007; 55(3): 379–387.
  69. Wu TH, Lee LJH, Yuan CT, et al. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients. A Taiwanese study. J Formos Med Assoc. 2019; 118(1 Pt 2): 230–236.
  70. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21(14): 2636–2644.
  71. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase III trial. Lancet. 2016; 387(10026): 1405–1414.
  72. Katirtzoglou N, Gkiozos I, Makrilia N, et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer. 2010; 11(1): 30–35.
  73. Ceresoli GL, Zucali PA, Mencoboni M, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006; 24(9): 1443–1448.
  74. Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008; 19(2): 370–373.
  75. Arrieta O, López-Macías D, Mendoza-García VO, et al. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2014; 73(5): 975–982.
  76. van Haarst JMW, Baas P, Manegold Ch, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002; 86(3): 342–345.
  77. Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002; 87(5): 491–496.
  78. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019; 20(2): 239–253.
  79. Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019; 7(3): 260–270.
  80. Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017; 18(5): 623–630.
  81. Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018; 13(10): 1569–1576.
  82. Metaxas Y, Rivalland G, Mauti LA, et al. Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. J Thorac Oncol. 2018; 13(11): 1784–1791.
  83. Kindler HL, Ismaila N, Armato SG, et al. Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2018; 36(13): 1343–1373.
  84. Foroudi F, Smith JG, Putt F, et al. High-dose palliative radiotherapy for malignant pleural mesothelioma. J Med Imaging Radiat Oncol. 2017; 61(6): 797–803.
  85. Graaf-Strukowska Lde, Zee Jv, Putten Wv, et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura — a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys. 1999; 43(3): 511–516.
  86. Ashton M, O'Rourke N, Currie S, et al. The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review. Radiother Oncol. 2017; 125(1): 1–12.
  87. Flores RM, Krug LM, Rosenzweig KE, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001; 122(4): 788–795.
  88. Gomez DR, Hong DS, Allen PK, et al. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013; 8(2): 238–245.
  89. Yajnik S, Rosenzweig KE, Mychalczak B, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003; 56(5): 1319–1326.
  90. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007; 84(5): 1685–92; discussion 1692.
  91. Baldini EH, Jänne PA, Baldini EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin. 2004; 14(4): 567–573.
  92. van Thiel ERE, Surmont VF, van Meerbeeck JP. Malignant pleural mesothelioma: when is radiation therapy indicated? Expert Rev Anticancer Ther. 2011; 11(4): 551–560.
  93. Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005; 63(4): 1045–1052.
  94. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995; 108(3): 754–758.
  95. O'Rourke N, Garcia JC, Paul J, et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol. 2007; 84(1): 18–22.
  96. Bydder S, Phillips M, Joseph DJ, et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer. 2004; 91(1): 9–10.
  97. Clive AO, Taylor H, Dobson L, et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016; 17(8): 1094–1104.
  98. Verma V, Ahern CA, Berlind CG, et al. National cancer database report on pneumonectomy versus lung-sparing surgery for malignant pleural mesothelioma. J Thorac Oncol. 2017; 12(11): 1704–1714.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl